IMMOBLIZED CHELATOR FOR EXTRACORPOREAL LEAD REMOVAL

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 16746
Amount: $475,980.00
Phase: Phase II
Program: SBIR
Awards Year: 1992
Solitcitation Year: N/A
Solitcitation Topic Code: N/A
Solitcitation Number: N/A
Small Business Information
Hemex Inc.
143 Windsor Ave., Buffalo, NY, 14209
Duns: N/A
Hubzone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Principal Investigator
 () -
Business Contact
 1 R43 HL47662-01
Phone: () -
Research Institution
N/A
Abstract
RECENT REPORTS ESTIMATE THE NUMBER OF CHILDREN WITH LEAD INTOXICATION AT 230,000, THE NUMBER OF INDUSTRIAL WORKERS WITH LEAD POISONING AT 530,000. THESE NUMBER CREATE A MEDICAL PROBLEM OF ALARMING MAGNITUDE, BECAUSE TREATMENT WITH AVAILABLE CHELATORS HAS SERIOUS SIDE-EFFECTS. EVEN THE CHELATOR-LEAD COMPLEXES THAT FORM IN THE BLOOD DURING TREATMENT ARE DAMAGING THE KIDNEYS DURING ELIMINATION. WE HAVE DEVELOPED A POLYSULFONE HOLLOW-FIBER DEVICE WITH IMMOBILIZED CHELATORS, FOR THE EXTRACORPOREAL REMOVAL OF LEAD FROM BLOOD AND SUBSEQUENTLY FROM STORAGE SITES. SINCE THE CHELATOR IS IMMOBILIZED THE CHELATION PROCESS OCCURS OUTSIDE OF THE CIRCULATION, AND TOXICITY OF LEAD AND LEAD-CHELATOR COMPLEX IS ELIMINATED. THE GOAL IN THE PHASE I STUDIES IS TO EXPLORE THE FEASIBILITY OF DEVELOPING A LEAD-CHELATOR DEVICE OF CLINICALSIGNIFICANCE. CHELATOR FUNCTIONS WILL BE SYNTHESIZED ON VARIOUS SUPPORTS AND LEAD BINDING CAPACITY TESTED COLLOIDAL SUSPENSIONS WILL BE PREPARED FROM THESE CHELATORS AND TESTED FOR CAPACITY AND LEAD SPECIFICITY. BY STEP-WISE SELECTION, THE MOST PROMISING AGENTS WILL BE LOADED INTO HOLLOW FIBER CARTRIDGES AND EVALUATED FOR CAPACITY, SPECIFICITY, AND KINETICS OF LEAD REMOVAL. RESULTS WILL HELP SELECT THE OPTIMAL CHELATOR TO DEVELOP A PROTOTYPE FOR CLINICAL USE WITH PHASE II SUPPORT. RECENT REPORTS ESTIMATE THE NUMBER OF CHILDREN WITH LEAD INTOXICATION AT 230,000, THE NUMBER OF INDUSTRIAL WORKERS WITH LEAD POISONING AT 530,000. THESE NUMBER CREATE A MEDICAL PROBLEM OF ALARMING MAGNITUDE, BECAUSE TREATMENT WITH AVAILABLE CHELATORS HAS SERIOUS SIDE-EFFECTS. EVEN THE CHELATOR-LEAD COMPLEXES THAT FORM IN THE BLOOD DURING TREATMENT ARE DAMAGING THE KIDNEYS DURING ELIMINATION. WE HAVE DEVELOPED A POLYSULFONE HOLLOW-FIBER DEVICE WITH IMMOBILIZED CHELATORS, FOR THE EXTRACORPOREAL REMOVAL OF LEAD FROM BLOOD AND SUBSEQUENTLY FROM STORAGE SITES. SINCE THE CHELATOR IS IMMOBILIZED THE CHELATION PROCESS OCCURS OUTSIDE OF THE CIRCULATION, AND TOXICITY OF LEAD AND LEAD-CHELATOR COMPLEX IS ELIMINATED. THE GOAL IN THE PHASE I STUDIES IS TO EXPLORE THE FEASIBILITY OF DEVELOPING A LEAD-CHELATOR DEVICE OF CLINICALSIGNIFICANCE. CHELATOR FUNCTIONS WILL BE SYNTHESIZED ON VARIOUS SUPPORTS AND LEAD BINDING CAPACITY TESTED COLLOIDAL SUSPENSIONS WILL BE PREPARED FROM THESE CHELATORS AND TESTED FOR CAPACITY AND LEAD SPECIFICITY. BY STEP-WISE SELECTION, THE MOST PROMISING AGENTS WILL BE LOADED INTO HOLLOW FIBER CARTRIDGES AND EVALUATED FOR CAPACITY, SPECIFICITY, AND KINETICS OF LEAD REMOVAL. RESULTS WILL HELP SELECT THE OPTIMAL CHELATOR TO DEVELOP A PROTOTYPE FOR CLINICAL USE WITH PHASE II SUPPORT.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government